Welcome to our dedicated page for Onco-Innovations news (Ticker: ONNVF), a resource for investors and traders seeking the latest updates and insights on Onco-Innovations stock.
News for Onco-Innovations Limited (ONNVF) centers on its activities in oncology research, preclinical drug development, AI-enabled precision medicine, and corporate financing. The company describes itself as a Canadian-based oncology-focused organization with an exclusive worldwide license to patented technology targeting solid tumours, including its PNKP Inhibitor Technology platform.
Investors and observers following Onco-Innovations’ news can expect updates on the advancement of its PNKP Inhibitor Technology (A83B4C63), including manufacturing milestones with Dalton Pharma Services such as process optimization, intermediate scale-up, analytical method development, and preparation for potential future clinical material production. Releases also cover collaborations with partners like Kuano Ltd., where quantum-ready molecular modelling and AI-driven compound design are being applied to deepen understanding of PNKP inhibition and guide next-generation therapeutic candidates.
Another important stream of news involves Onco-Innovations’ subsidiary Inka Health and its SynoGraph platform. Announcements have highlighted publications on the transportability of real-world evidence, integration of advanced statistical methods into SynoGraph, and participation in precision oncology forums with organizations such as Colorectal Cancer Canada. These items illustrate how the company links AI, real-world data, and oncology decision-making.
Corporate and capital markets developments also feature in the news flow. Onco-Innovations has reported private placements, board appointments, marketing engagements, and its intention to pursue a potential Nasdaq cross-listing with the support of a U.S. investment bank. For a consolidated view of these scientific, strategic, and financing updates, this news page provides a single location to review the company’s disclosed developments over time.
Onco-Innovations (OTCQB:ONNVF) announced on December 7, 2025 that it has engaged a U.S. investment bank to advise on a potential Nasdaq cross-listing and to evaluate a possible concurrent equity financing.
The advisory mandate covers analysis of listing requirements, regulatory and governance considerations, and capitalization strategies to support a U.S. cross-listing. The company said the structure and terms of any financing are not finalized and that there is no assurance a cross-listing or financing will be completed.
Onco-Innovations (OTCQB:ONNVF) attended the University of Alberta's 2025 Innovation Awards on November 21, 2025, highlighting its 2024 exclusive license of the PNKP Inhibitor Technology from the university.
The technology, developed over more than 15 years, is supported by nine issued patents and aims to sensitize cancer cells to chemotherapy and radiation by delaying DNA repair. Onco-Innovations said it is advancing preclinical development and IND-enabling studies toward clinical evaluation. The company also approved issuance of 60,000 Restricted Share Units to certain directors under its equity incentive plan.
Onco-Innovations (OTCQB:ONNVF) said Dalton Pharma Services began optimization and intermediate scale-up for its proprietary PNKP inhibitor A83B4C63 on November 20, 2025. The program advances from prior preclinical manufacturing to pilot-scale, non‑GMP synthesis using Dalton's FDA- and Health Canada‑approved Toronto facility.
Key activities include intermediary batches targeting approximately 500 g of precursor A83 and 1,000 g of precursor B4, analytical method qualification, ICH‑guided stability testing, and a formal safety and risk assessment to support future GMP production and IND‑enabling work toward Phase 1 studies.
Onco-Innovations (OTCQB:ONNVF) announced a pilot collaboration with Kuano to accelerate development of its PNKP Inhibitor Technology (A83B4C63) using AI, molecular modelling and Kuano's quantum-ready analytics.
The pilot runs through Q4 2025 and aims to deliver validated platform outputs, structural binding models, and mechanistic hypotheses to guide structure optimization, generative design, toxicity mapping, and preclinical candidate selection.
Onco-Innovations (OTCQB:ONNVF) announced that subsidiary Inka Health published a technical primer titled Transportability of Non-Local Real-World Evidence in the Journal of Clinical Evaluative Research on November 7, 2025. The primer outlines three foundational principles — consistency, positivity, conditional exchangeability — and describes statistical techniques (matching, weighting, standardization, bias analysis) to adapt non-local RWE for Health Technology Assessment.
Inka Health plans to integrate these methods into its SynoGraph platform to support cross-border oncology evidence use, especially for rare diseases with limited local data.
Onco-Innovations (OTCQB:ONNVF) provided a shareholder update outlining 2026 priorities, emphasizing a U.S. growth strategy and clinical translation.
Key 2025 milestones cited include the acquisition of Inka Health AI (Feb 2025), moving its stock listing to the Cboe Canada Market, partnerships with Dalton Pharma (May 2025), collaboration with the University of Alberta and Cross Cancer Institute (June 2025), an agreement with Nucro-Technics (July 2025), and a start-up agreement with Avance Clinical. The company says it is preparing for a Phase 1 clinical trial in 2026 and plans to pursue a U.S. stock exchange cross-listing in 2026 to broaden investor access and R&D engagement.
Onco-Innovations (OTCQB:ONNVF) appointed Jared Rushton to its Board of Directors, effective October 30, 2025, replacing Zachary Stadnyk.
Mr. Rushton brings over a decade of public markets experience in corporate development, strategic advisory and capital markets planning across mining, cannabis and biotech sectors.
The company also engaged MCS Market Communication Service GmbH for online marketing services through December 15, 2025 (or until budget exhaustion) and paid EUR 600,000 in consideration; no securities were issued to MCS. Services include Google Ads, native advertising, campaign creation, and analytics.
Onco-Innovations (OTCQB:ONNVF) closed a non-brokered private placement on October 27, 2025, issuing 1,428,570 units at $1.40 per unit for aggregate gross proceeds of $2,000,000. Each unit comprises one common share and one-half of one warrant; warrants are exercisable at $2.00 per share for 36 months. The company paid finders $119,999.94 and issued 85,714 warrants, and issued 14,286 administrative shares for services. Proceeds are for general corporate and working capital purposes, including operational, R&D and investor relations objectives. All securities are subject to a four-month-and-one-day statutory hold and are not registered for sale in the United States.
Onco-Innovations (OTCQB:ONNVF) announced a non-brokered private placement of up to 1,428,572 units at $1.40 per unit to raise up to $2,000,000. Each unit includes one common share and one-half of a warrant, with each whole warrant exercisable at $2.00 for 36 months. The company will issue Admin Fee Shares equal to 1.0% of shares sold and may pay finders' fees or issue finders' warrants on similar terms. Proceeds are for general corporate and R&D purposes. Closing is subject to regulatory approvals and issued securities carry a four-month-and-one-day hold. The company also appointed Christopher Gulka to the board, succeeding Graydon Bensler.
Onco-Innovations (OTCQB:ONNVF) has announced the initiation of laboratory work for its IND-enabling program through Nucro-Technics, focusing on their Polynucleotide Kinase Phosphatase (PNKP) inhibitor technology.
The program centers on developing and validating analytical methods using liquid chromatography-mass spectrometry (LC-MS) to measure the PNKP Technology (A83B4C63) in animal model plasma and its polymer-based nanoparticle delivery system. These methods will support future toxicology and pharmacokinetics studies under GLP standards, required for FDA and Health Canada regulatory submissions.
The analytical tools will enable tracking of both free and encapsulated forms of the compound, providing crucial data on stability, metabolism, and drug exposure in vivo, essential for advancing towards human clinical trials.